43 related articles for article (PubMed ID: 21646468)
21. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
22. Novel drugs for older patients with acute myeloid leukemia.
Montalban-Bravo G; Garcia-Manero G
Leukemia; 2015 Apr; 29(4):760-9. PubMed ID: 25142817
[TBL] [Abstract][Full Text] [Related]
23. Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.
Chang KC; Chang WC; Chang Y; Hung LY; Lai CH; Yeh YM; Chou YW; Chen CH
PLoS One; 2013; 8(11):e79863. PubMed ID: 24223200
[TBL] [Abstract][Full Text] [Related]
24. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan AC; O'Rourke JJ; Praharaj DR; Felsher DW
Expert Opin Investig Drugs; 2013 Nov; 22(11):1495-509. PubMed ID: 23937225
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.
Ohnuma T; Lehrer D; Ren C; Cho SY; Maniar M; Silverman L; Sung M; Gretz HF; Benisovich V; Navada S; Akahoho E; Wilck E; Taft DR; Roboz J; Wilhelm F; Holland JF
Am J Cancer Res; 2013; 3(3):323-38. PubMed ID: 23841031
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Roschewski M; Farooqui M; Aue G; Wilhelm F; Wiestner A
Leukemia; 2013 Sep; 27(9):1920-3. PubMed ID: 23486532
[No Abstract] [Full Text] [Related]
28. Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice.
Lu M; Merali S; Gordon R; Jiang J; Li Y; Mandeli J; Duan X; Fallon J; Holland JF
Genes Cancer; 2011 Oct; 2(10):985-92. PubMed ID: 22701764
[TBL] [Abstract][Full Text] [Related]
29. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
Mross K; Dittrich C; Aulitzky WE; Strumberg D; Schutte J; Schmid RM; Hollerbach S; Merger M; Munzert G; Fleischer F; Scheulen ME
Br J Cancer; 2012 Jul; 107(2):280-6. PubMed ID: 22699824
[TBL] [Abstract][Full Text] [Related]
30. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Chapman CM; Sun X; Roschewski M; Aue G; Farooqui M; Stennett L; Gibellini F; Arthur D; Pérez-Galán P; Wiestner A
Clin Cancer Res; 2012 Apr; 18(7):1979-91. PubMed ID: 22351695
[TBL] [Abstract][Full Text] [Related]
31. In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
Lu T; Laughton CA; Wang S; Bradshaw TD
Mol Pharmacol; 2015 Jan; 87(1):18-30. PubMed ID: 25316768
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard.
Bhatia U; Danishefsky K; Traganos F; Darzynkiewicz Z
Clin Cancer Res; 1995 Aug; 1(8):873-80. PubMed ID: 9816057
[TBL] [Abstract][Full Text] [Related]
33. Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.
Oussenko IA; Holland JF; Reddy EP; Ohnuma T
Cancer Res; 2011 Jul; 71(14):4968-76. PubMed ID: 21646468
[TBL] [Abstract][Full Text] [Related]
34. RanGAP1*SUMO1 is phosphorylated at the onset of mitosis and remains associated with RanBP2 upon NPC disassembly.
Swaminathan S; Kiendl F; Körner R; Lupetti R; Hengst L; Melchior F
J Cell Biol; 2004 Mar; 164(7):965-71. PubMed ID: 15037602
[TBL] [Abstract][Full Text] [Related]
35. SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles.
Joseph J; Tan SH; Karpova TS; McNally JG; Dasso M
J Cell Biol; 2002 Feb; 156(4):595-602. PubMed ID: 11854305
[TBL] [Abstract][Full Text] [Related]
36. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
Dai YH; Hung LY; Chen RY; Lai CH; Chang KC
Transl Res; 2016 Sep; 175():129-143.e13. PubMed ID: 27150054
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
